Overview of Glucose anhydrous

Property	Description
Active ingredient	Glucose anhydrous (Dextrose)
Form	Solution for injection (Parenteral preparation)
Pharmacological class	Nutrient and Caloric Agent
Route of administration	Intravenous (IV)
Origin	Natural (purified monosaccharide)

Defining Glucose Anhydrous: Identity and Pharmacological Class

Glucose anhydrous, chemically known as Dextrose or D-glucose, is a foundational carbohydrate and an essential monosaccharide that functions as the primary fuel source for the body's metabolic activity. This substance is classified as a Nutrient and a potent Caloric Agent within clinical pharmacology, placing it in the category of intravenous fluids and electrolytes. Glucose is used for its critical role in medical settings. It is a compound of natural origin, identical to the glucose that circulates in the blood, and is highly purified for medical use to ensure immediate biological recognition and efficiency as a therapeutic agent.

Form and Composition of the Parenteral Preparation

The medicinal entity is prepared primarily as a sterile, non-pyrogenic solution for injection, making it a quintessential Parenteral preparation designed for rapid administration via the intravenous route. The composition is simple, featuring the active ingredient, Glucose anhydrous, dissolved in a base of Sterile water (Water for Injection). Depending on the clinical goal, these preparations are formulated to be either Isotonic (typically 5% concentration, balancing tonicity with blood plasma) or Hypertonic (higher concentrations). The D-glucose structure supports its role as a key component in fluid replenishment and energy management.

General Purpose: What is the Core Benefit of Dextrose?

The core benefit of administering Glucose anhydrous is to provide the body with a readily available energy source necessary to sustain vital organ functions, including those of the brain and heart. By delivering this immediate energy substrate, the solution serves to rapidly prevent or correct states of metabolic deficit. This action helps maintain the body's energy balance and contributes significantly to overall fluid replenishment in patients unable to meet their nutritional needs orally, ensuring the stabilization of fundamental physiological processes and the controlled elevation of blood glucose levels.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Glucose anhydrous?

Possible Side Effects and Safety Information

The safety profile of Glucose anhydrous (Dextrose) intravenous solutions focuses primarily on metabolic and fluid balance disturbances, as documented in regulatory labeling. Adverse events are often classified as Not Known (frequency cannot be estimated from available data) but relate to predictable physiological responses to the solution.

Key Adverse Reactions and Affected Systems

Adverse reactions most frequently affect the Metabolism and nutrition disorders and General disorders and administration site conditions system-organ classes. Common expected effects include:

Fluid and electrolyte disturbances: Such as hypokalemia (low potassium) or hypervolemia (fluid overload).
Hyperglycemia and Glycosuria: Elevated blood sugar and glucose in the urine, particularly with rapid infusion.
Administration site reactions: Local pain, irritation, or phlebitis at the injection site.

Serious Adverse Reactions

Serious adverse events documented in regulatory sources include Acute Hyponatraemic Encephalopathy, a severe form of brain swelling resulting from acute, low sodium levels (hyponatremia) caused by the solution becoming physiologically hypotonic in vivo. Other serious risks are Hyperosmolar Syndrome and severe Anaphylactic/Anaphylactoid Reactions.

Population-Specific Safety and Restrictions

Official labels identify pediatric patients (especially neonates) as being at particular risk of severe acute hyponatraemic encephalopathy and requiring close monitoring for hypo- or hyperglycemia. Safety constraints strictly prohibit use in patients with uncompensated diabetes, hyperosmolar coma, and typically restrict use in patients who have had head trauma within 24 hours or during episodes of intracranial hypertension. Monitoring of serum glucose, sodium, and fluid balance is required throughout administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents generally classify Glucose anhydrous as a substance of low toxicity, which is not expected to present a significant hazard under anticipated conditions of normal use. The overdose profile described is limited and primarily relates to excessive exposure.

Documented Overdose Presentations

Extremely large oral dosages may produce gastrointestinal disturbances.
Inhalation of excessive concentrations of the powdered form may affect individuals with impaired respiratory function or airway diseases like chronic bronchitis.

Required Emergency Actions (Official Regulatory Statements)

Exposure Route	Emergency Action (Label-Derived Phrasing)
Ingestion	Rinse mouth. Do NOT induce vomiting. Obtain emergency medical attention.
Inhalation	Remove victim to fresh air. If breathing is irregular or stopped, immediately seek medical assistance and start first aid actions.

When Immediate Medical Help is Required

Urgent medical attention is explicitly required in cases of ingestion, or if inhalation leads to severe signs, such as when breathing is irregular or stopped. In all cases where an individual feels unwell, they should seek medical advice. Never attempt to give anything by mouth to an unconscious person.

The regulatory focus for this substance is on standard chemical safety and first aid, given its low inherent toxicity and non-hazardous classification.

Therapeutic Uses of Glucose anhydrous

What Glucose Anhydrous Treats: Main Uses and Benefits

The therapeutic utility of Dextrose is applied across distinct areas of symptomatic support, including managing severe symptomatic hypoglycemia, addressing systemic nutrient deprivation in patients unable to eat, and providing support during acute electrolyte disturbances.

Rapid Relief for Symptoms of Acute Energy Crisis

This agent is commonly used for intervention in severe symptomatic hypoglycemia, a medical state marked by critically low blood sugar. It is relevant for easing the alarming symptoms that arise from the brain's energy deprivation, including sudden confusion, profound weakness, and excessive sweating. The key therapeutic benefit is that it is used for managing symptoms that interfere with daily comfort, such as confusion and weakness, and may assist in easing the intensity of related neurological manifestations, contributing to maintaining a sense of stability during an acute metabolic crisis.

“It is commonly used when symptoms intensify and short-term symptomatic assistance is needed.”

Quick Fact: Relevant for Neurological Symptoms This treatment is applied in conditions where energy lack creates noticeable functional strain, assists with maintaining functional stability.

Caloric Support for Nutritional Deficit and Malabsorption

Glucose anhydrous is applied across domains where additional symptomatic support is needed, such as in supportive care. It is typically used when patients are unable to meet their energy needs orally. It helps manage systemic nutrient deprivation and chronic metabolic deficit. This assists with easing the overall symptom load related to energy lack and fatigue and supports general well-being during symptomatic phases.

Regulatory References

NIH DailyMed drug label

Eligibility and Restrictions for Use

Official Eligibility Profile: Glucose Anhydrous (Dextrose Injection)

Official regulatory documents define eligibility through strict contraindications and conditional restrictions based on patient status and age.

Absolute Non-Eligibility

The medicine is strictly contraindicated (must not be used) in populations presenting with:

Clinically significant hyperglycemia (high blood sugar).
Known hypersensitivity to dextrose or any component of the formulation.

Restricted and Conditional Use

Use is restricted or requires special caution in specific patient groups, as defined by official labeling:

Metabolic/Organ Function: Caution is required for patients with impaired glucose tolerance (such as diabetes mellitus) and those with impaired renal function.
High-Risk Conditions: Hypertonic solutions are prohibited in patients with intracranial or intraspinal hemorrhage or severe dehydration.
Age Groups: Neonates and very low birth weight infants require close monitoring due to increased risks of metabolic and neurological complications. Geriatric patients require cautious dose selection reflecting the frequency of decreased organ function.
Reproductive Status: The medicine is classified as FDA Pregnancy Category C and should be given only if clearly needed. Caution is advised for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Glucose anhydrous (Dextrose) primarily relate to its effects on glycemic control and electrolyte balance, as well as constraints concerning physical compatibility with other solutions.

Documented Interactions

Interaction Type	Interacting Medicines/Classes	Effect and Management
Physical/Procedural	Whole blood or packed red blood cells	Do not administer simultaneously through the same administration set. Concurrent administration can cause pseudoagglutination or hemolysis of red blood cells.
Pharmacodynamic (Glycemic)	Antidiabetic agents (e.g., insulin), Corticosteroids, beta2-agonists	Glucose may necessitate adjustments in the dosing of antidiabetic agents. Drugs that influence glucose metabolism may either enhance or reduce the hyperglycemic effect of Dextrose.
Pharmacodynamic (Electrolyte)	Diuretics, Arginine vasopressin receptor antagonists (AVP antagonists)	Co-administration may increase the risk of developing hyponatremia and other electrolyte disturbances. Close monitoring of serum electrolytes is warranted.
Chemical/Incompatibility	Various Additives and Chemotherapy Agents	Additives must be checked for compatibility with the glucose solution before mixing, as subtle physical or chemical incompatibilities may occur. Consult prescribing information for specific chemotherapy agents regarding appropriate diluents.

Key Considerations

The most critical restriction is the avoidance of simultaneous infusion with blood products. Compatibility assessments are mandatory before combining any other medicine with Dextrose solutions for infusion to ensure the stability and safety of the final mixture. The use of Dextrose in patients on medications affecting water or sodium balance requires vigilance due to the potential for electrolyte imbalances.

Mechanism of Action

Glucose anhydrous, once circulating, serves as the primary biological target for cellular energy metabolism. It does not function as an inhibitor, antagonist, or agonist but rather as a substrate for catabolic and anabolic pathways. The monosaccharide is transported across the plasma membrane into target cells, including muscle, adipose, and central nervous system tissue, primarily via Glucose Transporter (GLUT) proteins through facilitated diffusion.

Intracellularly, glucose initiates the glycolytic pathway through an initial phosphorylation step, converting it to glucose-6-phosphate. This key molecule is then metabolized through a cascade of ten enzymatic reactions in the cytosol, culminating in pyruvate production. Under aerobic conditions, pyruvate enters the mitochondria to fuel the citric acid cycle and subsequent oxidative phosphorylation cascade, which are the main intracellular pathways for the generation of adenosine triphosphate (ATP). This continuous ATP synthesis represents the downstream cascade. System-level, the modulation is a direct increase in circulating blood glucose concentration, thereby increasing the substrate availability for cellular respiration across energy-requiring organ systems.

Dosage and Administration Information

Instruction Map: How to use Glucose anhydrous — Official Administration Guidelines

The administration of Glucose anhydrous (Dextrose Injection) involves specific procedural adherence for patient safety and efficacy. This is for intravenous use only and must be administered by a healthcare professional.

Administration Scope

Classification	Rule
Route of administration	Intravenous Infusion
Dosing Schedule	The dosage is highly individualized based on the patient's age, weight, and metabolic condition. Infusion rate must be carefully controlled, especially in infants, to avoid hyperglycemia.
Timing in relation to meals	Not applicable; typically administered as continuous or intermittent support as part of medical therapy.
Preparation requirements	The solution must be visually inspected for particulate matter or discoloration before use. Do not use if the solution is cloudy or the seal is broken.
Age-group administration	Pediatric patients, particularly neonates and low birth weight infants, require careful selection of concentration and rate, and frequent monitoring of blood glucose levels.
Special procedural conditions	Solutions with a final concentration greater than 5% or an osmolarity of ≥ 900 mOsm/L should be administered through a central vein to reduce the risk of phlebitis and vein thrombosis. Do not administer simultaneously with blood products through the same administration set due to the risk of pseudoagglutination or hemolysis.

Resulting Procedural Structure

Official Step Sequence:

Visually inspect the solution for clarity and container for damage; discard if compromised.
If additives are required, mix thoroughly using aseptic technique and ensure the final solution remains clear with no precipitates.
Select the appropriate vein access based on the concentration: Peripheral vein for ≤ 5% concentrations; Central vein for concentrations > 5% or hyperosmolar solutions.
Administer via continuous slow intravenous infusion. Infusion rates must not be excessive.
Monitor the patient's blood glucose, fluid balance, and electrolyte levels frequently during administration. The unused portion must be discarded.

Connection to the overall use protocol: The protocol for Dextrose Injection is defined by a set of preparation and administration steps centered on intravenous delivery and strict rate control. This procedure emphasizes the necessity of concentration-dependent vein selection and biochemical monitoring to manage the risks associated with fluid and solute shifts during continuous infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Glucose Anhydrous

Evidence for Acute Correction of Severe Hypoglycemia

Research examining Glucose anhydrous (Dextrose) primarily focuses on the context of conditions associated with acute or disruptive episodes where immediate metabolic support is provided. Studies exploring this clinical situation include Randomized Controlled Trials (RCTs) and Observational Studies conducted in emergency settings. These research efforts were used in research exploring how symptoms change over time and applied in research contexts involving fluctuating or unstable symptoms.

Studies monitored outcomes related to blood glucose change (a biomarker) and the time interval over which levels evolved. Research also examined functional outcomes, specifically the time to changes in acute neurological symptoms or changes in consciousness levels. Studies reported patterns related to these measurements, and the evidence contributes to the broader evidence landscape.

There is limited information for comparative evidence related to the specific optimal concentration of Dextrose for administration across all populations. Furthermore, the evidence primarily focuses on immediate, short-term outcomes during the acute event, and long-term functional and safety outcomes are not fully established by these specific trials.

Evidence for Metabolic and Caloric Support

Research examined Dextrose as a potential caloric and fluid agent for patients who cannot meet their energy needs orally. This research examined temporary physiological imbalance and systemic nutrient deprivation. The evidence base relies on RCTs, Systematic Reviews, and Meta-analyses conducted in settings like critical care and general hospitalization.

Researchers monitored biomarker shifts related to metabolic status, such as changes in serum ketone levels (outcomes related to systemic or functional imbalance), and the maintenance of fluid and electrolyte balance. Studies reported how symptoms evolved in the observed populations, and described the use of Dextrose as a component in comprehensive parenteral nutrition protocols.

Evidence quality varies across studies, making the isolated contribution of Dextrose alone uncertain. Findings were mixed or heterogeneous regarding the use of Dextrose in specific high-risk subgroups, and data are still emerging in certain areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Glucose anhydrous (FAQ)

Q: Is Glucose anhydrous the same as regular sugar?

Glucose anhydrous is the chemical name for dextrose, a monosaccharide (simple sugar) that is identical to the glucose circulating in the body. While regular table sugar (sucrose) has a different chemical structure, both substances function as sources of caloric energy. The official product information specifies its classification as a nutrient and caloric agent.

Q: Does Glucose anhydrous cause weight gain?

As an official caloric agent, dextrose (Glucose anhydrous) provides approximately 3.4 kilocalories per gram when administered. Its primary role is to supply energy. If the total caloric intake provided by the infusion and other sources exceeds the body's energy expenditure, it is possible that it may contribute to weight maintenance or gain, similar to any other calorie source.

Q: What are the risks of using Glucose anhydrous for a long time?

Official warnings indicate that prolonged use requires careful monitoring by a healthcare professional. Using the infusion in large volumes or high concentrations over time is associated with risks of fluid overload or significant electrolyte imbalances (such as low sodium). Additionally, abruptly stopping the infusion after prolonged use can result in a drop in blood sugar called severe hypoglycemia.

Q: Is Glucose anhydrous considered a high-risk medication?

While the substance itself is a simple nutrient, the official product label contains multiple Warnings and Precautions that require stringent clinical management. These warnings address serious potential risks, including severe fluid and electrolyte imbalance, hyperosmolar states, and acute allergic reactions. For this reason, the administration process necessitates careful patient monitoring.

Q: Is Glucose anhydrous FDA-approved for specific medical conditions?

Regulatory documents indicate that Dextrose Injection is officially approved for use as a reliable source of water and calories for patients who require hydration and nutritional support. It is also specifically indicated for the treatment of insulin-induced hypoglycemia (low blood sugar) in appropriate clinical settings.

Q: What should I tell my doctor about other medicines before getting Glucose anhydrous?

Regulatory warnings recommend considering disclosure of all medications to your healthcare team, including prescription and non-prescription products. According to the official product information, special attention should be given to any medicines that may affect your fluid balance, electrolyte levels, or your blood glucose control.

Q: Does Glucose anhydrous contain gluten or common allergens?

The regulatory documentation advises caution regarding potential allergies. Solutions containing dextrose may be contraindicated (should not be used) in patients with a known hypersensitivity to dextrose. In some cases, official sources also note that a known allergy to corn products may be a concern, as dextrose is often derived from corn.

Q: Why is Glucose anhydrous sometimes used as a vehicle for other drugs?

The official indications state that Dextrose Injection is used as a diluent and delivery system for other compatible drug additives. The official documentation indicates that it acts as a diluent and delivery system for compatible additives.

Q: Is it normal to feel thirsty after getting Glucose anhydrous?

While thirst is not explicitly listed as a common side effect, official warnings caution that high doses can lead to hyperglycemia (high blood sugar). This elevated sugar level increases the concentration of the blood, which is associated with changes in fluid levels and may be a factor in feeling thirsty.

Q: What is the purpose of the 'anhydrous' part of the name?

The regulatory identity of the active substance refers to it as Glucose anhydrous. However, the product commonly used in medicine is Dextrose Monohydrate, meaning the glucose molecule is formulated with one molecule of water for stability. The term 'anhydrous' simply indicates the pure glucose molecule itself, without water attached.

Q: Why is Glucose anhydrous sometimes mixed with saline?

According to official product descriptions, Dextrose is frequently prepared as a combination with sodium chloride (saline). This combination ensures that the infusion provides not only a source of water and calories but also key electrolytes (salt) to support the maintenance of the body's delicate fluid and electrolyte balance.

Q: How is Glucose anhydrous different from fructose or sucrose?

The regulatory label describes Glucose anhydrous (dextrose) as a hexose sugar (a monosaccharide) that is quickly metabolized for energy. The label does not provide a direct comparison to other sugars, but its chemical structure and metabolic pathway are different from those of fructose or the more complex sucrose.

Q: Can people with heart disease safely receive Glucose anhydrous?

Official guidelines state that Dextrose injections should be used with care in patients who have cardiac insufficiency (heart weakness) or pre-existing fluid retention. Excessive infusion volume may pose a risk to these patients, which poses a risk of circulatory complications, particularly fluid overload.

Q: Can I receive Glucose anhydrous if I have liver disease?

The official eligibility profile lists specific restrictions for patients with severe liver issues. The medicine is contraindicated (must not be used) in patients who are in hepatic coma. Additionally, patients with liver cirrhosis require controlled infusion to manage the risk of water retention, as stated in the product information.

Q: Does Glucose anhydrous affect blood pressure?

The list of documented adverse reactions includes reports of both hypotension (low blood pressure) and volume overload, both of which are conditions that can influence a patient's blood pressure. For this reason, monitoring of the patient’s vital signs is part of the required administration process.

Q: Can certain diets affect how Glucose anhydrous works?

Official warnings caution that severely undernourished patients require special care. These patients are at risk for Refeeding Syndrome when reintroducing nutrition, and management involves a controlled, slow increase of nutrient intake as part of close monitoring.

How should Glucose anhydrous be stored and disposed of?

Storage and Disposal of Glucose Anhydrous Intravenous Infusion

Glucose anhydrous (Dextrose) intravenous infusion must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The solution must be protected from freezing. Exposure to freezing temperatures is a prohibited storage condition.

Storage and Handling

The solution must be visually inspected before use; do not use if the solution is cloudy, discolored, or contains visible particles.
If the solution has been mixed with other additives, it is for immediate use only and must not be stored.
The product must be kept out of the sight and reach of children.

Disposal Instructions

Since the product is for single use only, any unused portion must be discarded. Disposal of all unused product and waste material must be done according to local requirements for pharmaceutical waste.

Glucose anhydrous